Genistein in Triple-Negative Breast Cancer: Anticancer Mechanisms and Structural Modifications
Yaling Peng1, Simin Li2, Xing Zheng1,2
1Institute of Pharmacy and Pharmacology, Hengyang Medicinal School, University of South China, Hengyang, Hunan, China.
Abstract:
Genistein, a naturally occurring isoflavone with broad-spectrum bioactivities, is reviewed in this manuscript, with a specific focus on its anticancer mechanisms, structural modifications, and clinical progress. The cytotoxic activity displayed by genistein, particularly on in vitro tumor cell lines of triple-negative breast cancer, is extensively discussed. Although its exact mechanism of action continues to be explored, in vitro studies suggest genistein performs its inhibitory action through specific interference with cancer cell proliferation and growth. Despite these promising findings, the weak lipophilicity, instability, and low bioavailability limited the further application of genistein in clinical treatment. To address this challenge, structural modifications are proposed to genistein to improve its bioavailability and efficacy and reduce its toxicity.
Insights
Genistein shows anticancer effects, especially against triple-negative breast cancer cells. Structural modifications are needed to improve its clinical use due to low bioavailability and stability.
Area of Science:
- Natural Products Chemistry
- Cancer Biology
- Pharmacology
Background:
- Genistein is a naturally occurring isoflavone with diverse biological activities.
- It exhibits cytotoxic effects on various cancer cell lines, including triple-negative breast cancer.
- Its anticancer mechanisms involve interfering with cancer cell proliferation and growth.
Purpose of the Study:
- To review the anticancer mechanisms of genistein.
- To discuss structural modifications aimed at improving genistein's therapeutic potential.
- To summarize the clinical progress of genistein as an anticancer agent.
Main Methods:
- Literature review focusing on genistein's anticancer properties.
- Analysis of in vitro studies on genistein's cytotoxic activity.
- Examination of research on structural modifications and clinical trials.
Main Results:
- Genistein demonstrates significant in vitro cytotoxic activity against cancer cells, particularly triple-negative breast cancer.
- Proposed structural modifications aim to enhance genistein's lipophilicity, stability, and bioavailability.
- Challenges remain in translating in vitro findings to effective clinical applications.
Conclusions:
- Genistein holds promise as an anticancer therapeutic, with ongoing research into its mechanisms.
- Structural modifications are crucial for overcoming genistein's pharmacokinetic limitations.
- Further clinical studies are necessary to establish genistein's efficacy and safety in cancer treatment.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:15Drugs that Stabilize Microtubules
02:55The Nucleolus